Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus VANCERIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus VANCERIL.
ARNUITY ELLIPTA vs VANCERIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine production in the airways.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
2 inhalations (84 mcg) 3-4 times daily via oral inhalation.
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Terminal elimination half-life is approximately 2.8 hours in adults; prolonged in patients with hepatic impairment.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Primarily hepatic metabolism; <10% excreted unchanged in urine, <5% in feces.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid